These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 16359642)

  • 1. Dihydrofolate reductase inhibitors as antibacterial agents.
    Hawser S; Lociuro S; Islam K
    Biochem Pharmacol; 2006 Mar; 71(7):941-8. PubMed ID: 16359642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity.
    Oefner C; Bandera M; Haldimann A; Laue H; Schulz H; Mukhija S; Parisi S; Weiss L; Lociuro S; Dale GE
    J Antimicrob Chemother; 2009 Apr; 63(4):687-98. PubMed ID: 19211577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus.
    Oefner C; Parisi S; Schulz H; Lociuro S; Dale GE
    Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):751-7. PubMed ID: 19622858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening.
    Wyss PC; Gerber P; Hartman PG; Hubschwerlen C; Locher H; Marty HP; Stahl M
    J Med Chem; 2003 Jun; 46(12):2304-12. PubMed ID: 12773035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines.
    Li X; Hilgers M; Cunningham M; Chen Z; Trzoss M; Zhang J; Kohnen L; Lam T; Creighton C; G C K; Nelson K; Kwan B; Stidham M; Brown-Driver V; Shaw KJ; Finn J
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5171-6. PubMed ID: 21831637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfa and trimethoprim-like drugs - antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors.
    Capasso C; Supuran CT
    J Enzyme Inhib Med Chem; 2014 Jun; 29(3):379-87. PubMed ID: 23627736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections.
    Sincak CA; Schmidt JM
    Ann Pharmacother; 2009 Jun; 43(6):1107-14. PubMed ID: 19435963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents.
    Singh P; Kaur M; Sachdeva S
    J Med Chem; 2012 Jul; 55(14):6381-90. PubMed ID: 22734697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting DHFR in parasitic protozoa.
    Anderson AC
    Drug Discov Today; 2005 Jan; 10(2):121-8. PubMed ID: 15718161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action.
    Laue H; Weiss L; Bernardi A; Hawser S; Lociuro S; Islam K
    J Antimicrob Chemother; 2007 Dec; 60(6):1391-4. PubMed ID: 17962215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase.
    Bastien D; Ebert MC; Forge D; Toulouse J; Kadnikova N; Perron F; Mayence A; Huang TL; Vanden Eynde JJ; Pelletier JN
    J Med Chem; 2012 Apr; 55(7):3182-92. PubMed ID: 22424148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basis of selectivity of antibacterial diaminopyrimidines.
    Baccanari DP; Kuyper LF
    J Chemother; 1993 Dec; 5(6):393-9. PubMed ID: 8195830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cloning and characterization of a novel trimethoprim-resistant dihydrofolate reductase from a nosocomial isolate of Staphylococcus aureus CM.S2 (IMCJ1454).
    Sekiguchi J; Tharavichitkul P; Miyoshi-Akiyama T; Chupia V; Fujino T; Araake M; Irie A; Morita K; Kuratsuji T; Kirikae T
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3948-51. PubMed ID: 16127079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and comparative studies of zebrafish and human recombinant dihydrofolate reductases--inhibition by folic acid and polyphenols.
    Kao TT; Wang KC; Chang WN; Lin CY; Chen BH; Wu HL; Shi GY; Tsai JN; Fu TF
    Drug Metab Dispos; 2008 Mar; 36(3):508-16. PubMed ID: 18056255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brodimoprim, a new bacterial dihydrofolate reductase inhibitor: a minireview.
    Periti P
    J Chemother; 1995 Jun; 7(3):221-3. PubMed ID: 7562018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim.
    Heaslet H; Harris M; Fahnoe K; Sarver R; Putz H; Chang J; Subramanyam C; Barreiro G; Miller JR
    Proteins; 2009 Aug; 76(3):706-17. PubMed ID: 19280600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
    Forsch RA; Queener SF; Rosowsky A
    Bioorg Med Chem Lett; 2004 Apr; 14(7):1811-5. PubMed ID: 15026078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, biological evaluation and computational investigation of novel inhibitors of dihydrofolate reductase of opportunistic pathogens.
    Bag S; Tawari NR; Degani MS; Queener SF
    Bioorg Med Chem; 2010 May; 18(9):3187-97. PubMed ID: 20363634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.
    Wróbel A; Arciszewska K; Maliszewski D; Drozdowska D
    J Antibiot (Tokyo); 2020 Jan; 73(1):5-27. PubMed ID: 31578455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.